论文部分内容阅读
采取多中心随机对照试验的方法,对60例带状疱疹病人用泛昔洛韦片(由浙江海正药业股份有限公司研制)进行临床治疗研究。 结果:泛昔洛韦治疗带状疱疹的止疱时间平均为3.02±1.80天(对照组为4.05±1.61.P<0.05),结痂时间平均为5.24±3.02天(对照组为6.15±2.44,P>0.05),脱痂时间平均为11.22±3.38天(对照组为12.87±2.80,P<0.05),疼痛缓解时间平均为3.84±2.39天(对照组为5.40±3.44,P<0.05),急性神经痛持续时间平均为8.84±3.95天(对照组为10.95±3.99,P<0.05),后遗神经痛发生率为32.7％(对照组为50％,P>0.05)。不良反应发生率为7.27％(对照组为5.45％、P>0.05)。泛昔洛韦治疗带状疱疹疗效有所提高,耐受性好,不良反应少,服用剂量及次数少,患者易于接受,是治疗带状疱疹有效、安全的药物。
To take a multicenter randomized controlled trial of 60 patients with herpes zoster treatment of famciclovir tablets (Zhejiang Hisun Pharmaceutical Co., Ltd.) for clinical treatment. Results: The average blister time of famciclovir treatment for herpes zoster was 3.02 ± 1.80 days (4.05 ± 1.61, P <0.05 for control group), and the average time of scab was 5.24 ± 3.02 days (control group, 6.15 ± 2.44, P> 0.05 ), The average duration of excision of the scab was 11.22 ± 3.38 days (control group, 12.87 ± 2.80, P <0.05), the pain relief time was 3.84 ± 2.39 days (control group, 5.40 ± 3.44, P <0.05) The average time was 8.84 ± 3.95 days (control group, 10.95 ± 3.99, P <0.05). The incidence of postherpetic neuralgia was 32.7% (control group, 50%, P> 0.05). The incidence of adverse reactions was 7.27% (control group was 5.45%, P> 0.05). Famciclovir treatment of herpes zoster efficacy has been improved, well tolerated, fewer adverse reactions, taking small doses and times, the patient is easy to accept, is an effective and safe drug for the treatment of shingles.